Type 2 Diabetes

Dr. Charles Vega suggestion doctors be less prescriptive in suggestion diets to patients.

Drugs like semaglutide are able to treat both diabetes and obesity.

A cross-sectional study of NHANES data suggests lowering BMI thresholds for diabetes screening among racial/ethnic minority patients could improve diabetes diagnosis and lower risk of adverse outcomes.

Expert nephrologist Dr. Rajeev Raghavan elaborates on the American Diabetes Association guideline updates for patients with diabetic kidney disease during Pri-Med West.

Dr. Rajeev Raghavan talks about the role of SGLT2 inhibitors and GLP-1 receptor agonists as new therapeutics available to slow progression of chronic kidney disease.

Pri-Med West presenter Dr. Rajeev Raghavan highlights the key points of his nephrology talk and identifies trending topics in the field during an interview.

In this special edition ATTD Recap episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Drs. Diana Isaacs and Natalie Bellini provide insight from ATTD 2022, including the latest updates in the world of diabetes smartphone apps, smart insulin pens, and CGM systems.

Data from a study presented at the European Congress on Obesity details the effects of adherence to a vegan diet on cardiometabolic health using data obtained from randomized controlled trials assessing the effects of vegan diets as an intervention.

A 3-month trial found reducing sedentary time by just an hour per day was enough to produce statistically significant changes in biomarkers for cardiovascular risk among patients with metabolic syndrome.

These data further elucidate the relationship between mental health and diabetic retinopathy.

The study agent was otherwise not associated with an increased number of intravitreal injections over a 12-month period.

A review of data presented at ATTD 2022 dissects what features within smartphone applications created to improve diabetes management actually contribute to improved glycemic control.

New research found veterans with diabetes who took L-DOPA and dopamine agonists showed delayed onset of vascular pathology associated with DR.

New data suggests the number of prescriptions for SGLT2 inhibitors in the US has doubled since 2015 with prescriptions for GLP-1 receptor agonists tripling during the same time period.

An RCT comparing a low carbohydrate diet against a Mediterranean diet in adolescents with T1D provides insight into the effects of both dietary approaches on glycemic control among these patients.

Participants with obesity or overweight lost up to 22.5% of their body weight with tirzepatide treatment.

In the April 2022 edition of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Drs. Diana Isaacs and Natalie Bellini discuss the implications of the FDA's approval of semaglutide 2.0 mg, the use of novel glycemic control metrics, and a preview of ATTD 2022.

The absolute reduction in LFC at week 52 was significantly greater for the pooled tirzepatide 10 mg and 15 mg groups versus the insulin degludec group.

Participants assigned to once-weekly tirzepatide spent significantly more time in tight target range at 52 weeks compared with those assigned to insulin degludec.

Dexamethasone as a first-line treatment for DME may increase economic costs in settings where bevacizumab is used off-label, but lower annual costs compared with aflibercept.

An analysis of the DAPA-HF trial provides insight into the occurrence of eGFR dips in the first 14 days following initiation of therapy with an SGLT2 inhibitor and their association with long-term outcomes.

An analysis of the REWIND trial suggests baseline cognitive impairment was associated with a 1.6 times greater risk of major adverse cardiovascular events among patients with type 2 diabetes.

Rural patients identifying as Black had a more than 10% absolute increased risk of major leg amputation or death compared with the overall cohort with diabetic foot ulcers.

Patients from the lowest BMI, HbA1c, SBP, and LDL-C population quartile had 3.9, 3.8, 1.9, and 0.9 years of additional life expectancy, respectively.

Dr Diana Isaacs provides insight on current challenges in the clinical treatment of patients with diabetes and shares clinical pearls for the use of CGMs in disease management.